COVID-19: Shionogi clinical trial in Southeast Asia: Vaccine supplied locally
Shionogi:
Under development of new coronavirus vaccine.
Conduct clinical trials in Southeast Asia such as Vietnam.
Confirmation of effectiveness:
The final large-scale clinical trial,
With the cooperation of Vietnam etc.
We have decided to focus on Southeast Asia.
Aim to conduct clinical trials of 30,000 cases.
Providing production technology to Asia:
It intends to contribute to the supply of vaccines in Asia by providing production technology.
Negotiations are underway with Southeast Asian countries other than Vietnam.
Vaccine under development by Shionogi:
It is different from Pfizer and Moderna mRNA.
A type called “recombinant protein vaccine”.
Conducted a medium-scale clinical trial in Japan in the fall,
Large-scale test will start within the year,
We are aiming for domestic supply within the year.
Measure the immune substances that can be produced in the body after inoculation.
Also consider how to compare with approved vaccine numbers.
–IZA!
https://www.iza.ne.jp/article/20210818-L2HJMLKTDVPY3LS7HAXQUJXUUM/
Shionogi, Corona drug for 1 million people this year: Nihon Keizai Shimbun
https://www.nikkei.com/article/DGKKZO74606220W1A800C2EA2000/